HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scientific background and the ongoing PETACC-8 trial.

Abstract
The standard adjuvant treatment for stage III colon cancer in Europe is the 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX-4) regimen, given for 6 months. Cetuximab, a monoclonal antibody directed against the EGF receptor, appears to be effective and safe when combined with oxaliplatin-based regimens, including FOLFOX-4, in patients with metastatic colorectal cancer. PETACC-8, a randomized, multicenter, European Phase III trial, is comparing the efficacy of cetuximab plus FOLFOX-4 with that of FOLFOX-4 alone in patients with stage III colon cancer. The study began in December 2005 and approximately 2000 patients are to be enrolled in nine European countries. The primary end point is disease-free survival time, analyzed after a minimum follow-up of 3 years per patient. Secondary end points include overall survival, treatment compliance, safety and pharmacogenomic parameters.
AuthorsJulien Taieb, Pierre Laurent Puig, Laurent Bedenne
JournalExpert review of anticancer therapy (Expert Rev Anticancer Ther) Vol. 8 Issue 2 Pg. 183-9 (Feb 2008) ISSN: 1744-8328 [Electronic] England
PMID18279058 (Publication Type: Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Organoplatinum Compounds
  • Cetuximab
  • Leucovorin
  • Fluorouracil
Topics
  • Antibodies, Monoclonal (administration & dosage)
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
  • Cetuximab
  • Chemotherapy, Adjuvant
  • Colectomy (methods)
  • Colonic Neoplasms (drug therapy, mortality, pathology, surgery)
  • Disease-Free Survival
  • Europe
  • Female
  • Fluorouracil (administration & dosage)
  • Humans
  • Leucovorin (administration & dosage)
  • Male
  • Neoplasm Invasiveness (pathology)
  • Neoplasm Staging
  • Organoplatinum Compounds (administration & dosage)
  • Prognosis
  • Survival Analysis
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: